reports
- Jacob Mekhael
- Thomas Vranken
- Sharad Kumar S.P
Holdings Report - May 2024 KBCS Holdings Universe Down -0.9% Due To Mu...
1M Performance - Absolute: Over the last 1M period, the KBCS Holdings Universe posted a return of -0.9% which was mainly driven by multi-asset holdings (-1.3%) while single-asset holdings posted a positive return of +0.6%. The 3 top performers during the period were Solvac (+8.0%), Gimv (+5.5%), and Compagnie du Bois Sauvage (+5.3%) while the 3 worst performers were HAL Trust (-6.5%), D'Ieteren Group (-1.8%), and Texaf (-1.1%). YTD Performance - Relative: On a YTD basis, the KBCS Holdings Univ...
GBLB GROUPE BRUXELLES LAMBERT SA
HAL HAL TRUST
DIE D'IETEREN SA
SOF SOFINA SA
SOLV SOLVAC S.A.
GIMB GIMV NV
QFG QUEST FOR GROWTH
ACKB ACKERMANS & VAN HAAREN NV
TUB FINANCIERE DE TUBIZE S.A.
HEIO HEINEKEN HOLDING N.V.
KBCA KBC ANCORA SCA
TEXF TEXAF
BREB BREDERODE S.A.
TINC TINC COMM. VA
ROCK WHITESTONE GROUP
EVS Communicates the Results of the Extraordinary General Meeting of J...
EVS Communicates the Results of the Extraordinary General Meeting of June 10, 2024 Publication on June 10, 2024, after market closureRegulated informationEVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS COMMUNICATES THE RESULTS OF THE EXTRAORDINARY GENERAL MEETING OF JUNE 10, 2024 EVS Broadcast Equipment SA, leading provider of live video production systems, held a postponed Extraordinary General Meeting on June 10, 2024 (due to the lack of attendance quorum at the Extraordinary General Meeting convened on May 21, 2024). In total 116 ...
- Jacob Mekhael
Inventiva Competitor results show impact on fibrosis in NASH/MASH
Yesterday, competitor Lilly (no coverage) reported a statistically significant effect on fibrosis in the phase 2 (SYNERGY-NASH, NCT04166773) trial of tirzepatide (GIP/GLP-1 agonist) in 155 biopsy-proven NASH/MASH patients. As a result, tirzepatide became the first incretin to hit on fibrosis with a 21-25% placebo adjusted response. While there was some read-through to other NASH/MASH stocks such as Madrigal and 89bio (both down approx. -3%), we believe NASH/MASH is a complex disease and high non...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update June 2024: Replacing ‘Gimv' and ‘TKH Grou...
Despite some large dividend payments (CP Invest, Bekaert, EVS, Solvay, TINC, Van de Velde, Ackermans & Van Haaren...) in our Dynamic Top Pick list in May 2024, our selection gained 1.6% on average, underperforming our benchmark indices (Bel20, AEX, EuroStoxx50) by -0.8% on average. Since the start of the 2024 selection (published on 14 December 2023), the Dynamic Top Pick list is up 15.2%, outperforming these indices by 3.7% on average. In this June 2024 update of our Dynamic Top Pick List, we ...
BEKB BEKAERT SA
ABN ABN AMRO BANK NV DEPOSITARY RECEIPTS
EVS EVS BROADCAST EQUIPMENT SA
SOLB SOLVAY SA
SOF SOFINA SA
GIMB GIMV NV
VAN VAN DE VELDE S.A.
IBAB ION BEAM APPLICATIONS SA
ACKB ACKERMANS & VAN HAAREN NV
TUB FINANCIERE DE TUBIZE S.A.
CPINV CARE PROPERTY INVEST SA
TWEKA TKH GROUP N.V. CERT
TINC TINC COMM. VA
ARGX ARGEN-X SE
ALFEN ALFEN NV
FUR FUGRO NV
SHUR SHURGARD SELF STORAGE LIMITED
SYENS SYENSQO
- Guy Sips
- Hilde Van Boxstael
- Lynn Hautekeete
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Xior Student Housing NV: 1 director
A director at Xior Student Housing NV bought 4,000 shares at 28.440EUR and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Michiel Declercq
- Wim Lewi
Combined General Meeting of June 20, 2024 - Availability of the prepar...
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of J...
Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposi...
Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoires Daix (France), Long Island City (New York, Etats-Unis), le 30 mai 2024 – Inventiva (Euronext Paris et Nasdaq : IVA), société́ biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de patients atteints de stéatohépatite non alcoolique (NASH) et d’autres maladies avec un besoin médical non satisfait, annonce aujourd’hui les modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 2...
Statement of total voting rights and shares forming the company’s shar...
Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024 Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code / Mnemo : FR0013233012 / IVAWeb site : Date Number of Shares Outstanding Total voting rights,gross (1) Total voting rights,net (2) May 13, 2024 52 477 188 65 493 081 65 381 630 (¹)The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is ca...
Information relative au nombre total de droits de vote et d’actions co...
Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024 Article R. 22-10-23 du Code de commerce Place de cotation : Euronext ParisCode ISIN / Mnémo : FR0013233012 / IVASite web : DateNombre de titres composant le capital en circulation Nombre total de droits de vote bruts(1) Nombre total de droits de vote nets(2)13 mai 202452 477 18865 493 08165 381 630 (¹) Le nombre de droits de vote bruts (ou droits de vote « théoriques ») sert de base de calcul pour les franchissements de seuil. Conformément à l’article 22...
EVS invites Its shareholders to an Extraordinary General Meeting on Ju...
EVS invites Its shareholders to an Extraordinary General Meeting on June 10, 2024 Publication on May 24, 2024, at 6:30 am before market openingRegulated informationEVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS INVITES ITS SHAREHOLDERS TO AN EXTRAORDINARY GENERAL MEETING ON JUNE 10, 2024 As already communicated on May 21, 2024, due to the lack of attendance quorum, the Extraordinary General Meeting of EVS Broadcast Equipment SA convened on May 21, 2024 is postponed to June 10, 2024, at 12:00 pm, at its registered office in Liège, to d...
EVS INVITE SES ACTIONNAIRES À UNE ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE RE...
EVS INVITE SES ACTIONNAIRES À UNE ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE REPORTEE LE 10 JUIN 2024 Publication le 24 mai 2024, à 6h30 avant l’ouverture du marchéInformation réglementée EVS Broadcast Equipment S.A.: Euronext Bruxelles (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS INVITE SES ACTIONNAIRES À UNE ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE REPORTEE LE 10 JUIN 2024 Comme déjà communiqué le 21 mai 2024, l’Assemblée Générale Extraordinaire de EVS Broadcast Equipment SA convoquée le 21 mai 2024 n’ayant pas réuni le quorum de présence requis est reportée au 10 juin 2024, à 12:00 heures, ...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Couvreur
- Wim Lewi
Inventiva announces two scientific presentations at the EASL Internati...
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024 The first abstract demonstrates that the improvements of MACK-3, a diagnostic test for metabolic dysfunction-associated steatohepatitis, parallel the histological response to lanifibranor therapy in patients with MASH/NASH, in the NATIVE Phase IIb clinical trial.The second abstract brings additional evidence supporting the role of intrahepatic vascular alterations in the development of MASLD-related portal hypertension and the progression to MASH and highlights the potential of lanifibranor in ad...
Inventiva annonce deux présentations scientifiques lors de l’EASL Inte...
Inventiva annonce deux présentations scientifiques lors de l’EASL International Liver Congress™ 2024 Le premier abstract démontre un parallèle entre les améliorations du score MACK-3, un test de diagnostic de la stéatohépatite associée à un dysfonctionnement métabolique, et la réponse histologique au traitement par lanifibranor chez les patients atteints de MASH/NASH, dans l’étude de phase IIb NATIVE.Le deuxième abstract apporte des évidences supplémentaires soutenant le rôle des altérations vasculaires intrahépatiques dans le développement de l'hypertension portale liée à MASLD et dans la...
- Hilde Van Boxstael
- Wim Lewi
- Jacob Mekhael
Inventiva FIRST LOOK: 1Q24 results reiterate NATiV3 last patient first...
Inventiva reported 1Q24 results with cash and cash equivalents of € 11m (YE23: € 26.9m), and deposits of € 19.1m (YE23: € 9m), which provides the company with a cash runway until the beginning of 3Q24. We are encouraged to see the timeline for the last patient first visit (LPFV) in the phase 3 (NATiV3) trial reiterated to 1H24, as it would provide timeline certainty by pinning the topline readout to 1H26. Inventiva's cash runway (early 3Q24) is sufficient to fund the company beyond the upcoming ...
Inventiva reports 2024 First Quarter Financial Information¹ and provid...
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update Cash and cash equivalents at €11.0 million, short-term2 deposits at €0.1million, and long-term deposit at €19.1 million3 as of March 31, 2024, compared to €26.9 million, €0.01 million and €9.0 million as of December 31, 2023, respectively.The fourth scheduled DMC meeting recommended to continue the NATiV3 Phase III clinical trial without modification of the current protocol, based on the pre-planned review of interim safety data of more than 900 patients randomized in the main and exploratory cohorts...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.